SOPHiA GENETICS (NASDAQ:SOPH) Hits New 1-Year High – Time to Buy?

Shares of SOPHiA GENETICS SA (NASDAQ:SOPH) reached a new 52-week high during mid-day trading on Monday . The company traded as high as $6.00 and last traded at $5.9810, with a volume of 195006 shares changing hands. The stock had previously closed at $5.75.

Analysts Set New Price Targets

Several brokerages recently issued reports on SOPH. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Tuesday, April 21st. BTIG Research reissued a “buy” rating and issued a $8.00 price objective on shares of SOPHiA GENETICS in a research note on Monday, June 15th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, SOPHiA GENETICS presently has an average rating of “Hold” and an average target price of $7.50.

SOPHiA GENETICS Trading Up 3.3%

The firm has a market capitalization of $498.22 million, a PE ratio of -11.38 and a beta of 0.98. The company has a quick ratio of 1.90, a current ratio of 2.06 and a debt-to-equity ratio of 1.05. The business’s fifty day moving average price is $5.07 and its 200 day moving average price is $4.92.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.04). SOPHiA GENETICS had a negative net margin of 44.48% and a negative return on equity of 62.74%. The firm had revenue of $21.69 million for the quarter, compared to analysts’ expectations of $20.40 million.

Insider Buying and Selling at SOPHiA GENETICS

In other news, CTO Abhimanyu Verma sold 6,944 shares of the company’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $5.51, for a total transaction of $38,261.44. Following the completion of the transaction, the chief technology officer owned 197,456 shares of the company’s stock, valued at $1,087,982.56. This represents a 3.40% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Jurgi Camblong sold 8,500 shares of the stock in a transaction dated Wednesday, June 10th. The stock was sold at an average price of $5.24, for a total transaction of $44,540.00. Following the transaction, the chief executive officer owned 3,620,995 shares in the company, valued at approximately $18,974,013.80. The trade was a 0.23% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 211,743 shares of company stock worth $1,043,419 in the last 90 days. 4.88% of the stock is owned by company insiders.

Hedge Funds Weigh In On SOPHiA GENETICS

A number of institutional investors have recently added to or reduced their stakes in SOPH. Royal Bank of Canada increased its position in shares of SOPHiA GENETICS by 3,130.2% during the first quarter. Royal Bank of Canada now owns 19,381 shares of the company’s stock worth $96,000 after acquiring an additional 18,781 shares during the last quarter. Sei Investments Co. acquired a new stake in SOPHiA GENETICS in the first quarter valued at $1,772,000. Principal Financial Group Inc. boosted its stake in SOPHiA GENETICS by 0.7% during the 1st quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company’s stock valued at $6,976,000 after acquiring an additional 9,800 shares during the last quarter. Hodges Capital Management Inc. bought a new position in SOPHiA GENETICS during the 1st quarter valued at $2,157,000. Finally, First Dallas Securities Inc. acquired a new position in SOPHiA GENETICS during the 1st quarter worth $50,000. Institutional investors and hedge funds own 31.59% of the company’s stock.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.